LUPIN PHARMACEUTICALS INC

Lobbying for LUPIN PHARMACEUTICALS INC

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 23, 2026

Expenses

$92,304.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Lobbyists on this filing 1

SHAWN BROWN ESQ

Previously held: VP Government Affairs

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Health Issues

Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.

Medicare/Medicaid

Reimbursement of generic pharmaceuticals and biosimilars.

Pharmacy

Country of Origin labeling.

Manufacturing

Incentivizing domestic manufacturing of essential medicines.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.